HLB Therapeutics Aims to Stage Comeback with RGN-259 Ahead of US Phase 3 Trial
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.4× normal (5 trading days)
Preview of a planned US Phase 3 trial; no new data or timing given.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.